首页> 美国卫生研究院文献>Elsevier Sponsored Documents >The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships
【2h】

The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships

机译:引入流感疫苗的伙伴关系(PIVI):通过公私伙伴关系支持中低收入国家的流感疫苗计划开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Influenza vaccination remains the most effective tool for reducing seasonal influenza disease burden. Few Low and Middle-Income Countries (LMICs) have robust, sustainable annual influenza national vaccination programs. The Partnership for Influenza Vaccine Introduction (PIVI) was developed as a public-private partnership to support LMICs to develop and sustain national vaccination programs through time-limited vaccine donations and technical support. We review the first 5 years of experience with PIVI, including the concept, country progress toward sustainability, and lesson learned. Between 2013 and 2018, PIVI worked with Ministries of Health in 17 countries. Eight countries have received donated vaccines and technical support; of these, two have transitioned to sustained national support of influenza vaccination and six are increasing national support of the vaccine programs towards full transition to local vaccine program support by 2023. Nine additional countries have received technical support for building the evidence base for national policy development and/or program evaluation. PIVI has resulted in increased use of vaccines in partner countries, and early countries have demonstrated progress towards sustainability, suggesting that a model of vaccine and technical support can work in LMICs. PIVI expects to add new country partners as current countries transition to self-reliance.
机译:流感疫苗接种仍然是减轻季节性流感疾病负担的最有效工具。很少有中低收入国家(LMIC)制定强有力的,可持续的年度流感国家疫苗接种计划。流感疫苗引进合作伙伴关系(PIVI)是作为公私合作伙伴关系而开发的,旨在通过有限的疫苗捐赠和技术支持来支持中低收入国家制定和维持国家疫苗接种计划。我们回顾了PIVI的前5年经验,包括概念,国家在可持续发展方面的进展以及所汲取的教训。在2013年至2018年期间,PIVI与17个国家的卫生部合作。八个国家收到了捐赠的疫苗和技术支持;其中,两个已经过渡到国家对流感疫苗的持续支持,六个正在增加对疫苗项目的国家支持,以在2023年前完全过渡到当地疫苗项目的支持。另外有九个国家获得了技术支持,以建立国家政策制定的证据基础和/或计划评估。 PIVI导致伙伴国家增加了疫苗的使用,早期国家在可持续性方面已显示出进展,这表明疫苗和技术支持模式可以在中低收入国家中发挥作用。 PIVI希望随着当前国家向自力更生的过渡增加新的国家伙伴。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号